Equities Analysts Set Expectations for Agenus Q1 Earnings

Agenus Inc. (NASDAQ:AGEN) – Analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Agenus in a research report issued to clients and investors on Tuesday, March 11th. William Blair analyst M. Phipps forecasts that the biotechnology company will post earnings per share of ($0.65) for the quarter. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. William Blair also issued estimates for Agenus’ Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.64) EPS and Q4 2026 earnings at ($0.64) EPS.

A number of other equities analysts have also commented on AGEN. Robert W. Baird cut their price objective on shares of Agenus from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Wednesday. HC Wainwright reiterated a “neutral” rating on shares of Agenus in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, Agenus presently has a consensus rating of “Hold” and a consensus target price of $8.75.

Agenus Trading Down 8.8 %

NASDAQ AGEN opened at $1.87 on Thursday. The stock has a market cap of $43.87 million, a P/E ratio of -0.17 and a beta of 1.23. The company’s fifty day simple moving average is $3.23 and its 200-day simple moving average is $3.84. Agenus has a 52 week low of $1.86 and a 52 week high of $19.69.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping the consensus estimate of ($2.36) by $0.32. The company had revenue of $26.84 million for the quarter, compared to analyst estimates of $30.09 million.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Barclays PLC lifted its holdings in Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 4,924 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Agenus by 46.1% in the third quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock valued at $122,000 after acquiring an additional 7,530 shares in the last quarter. State Street Corp boosted its holdings in shares of Agenus by 2.1% in the third quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after acquiring an additional 9,731 shares in the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Agenus during the third quarter valued at approximately $55,000. Finally, Point72 DIFC Ltd raised its holdings in Agenus by 380.0% during the third quarter. Point72 DIFC Ltd now owns 14,579 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 11,542 shares in the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.